Agonist News and Research

RSS

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

New insights into possible common links between neurodegenerative diseases

The pattern of brain alterations may be similar in several different neurodegenerative diseases, which opens the door to alternative therapeutic strategies to tackle these diseases

21 Apr 2014

OPKO Health enters into definitive agreement to acquire Inspiro Medical

OPKO Health, Inc. has entered into a definitive agreement to acquire Inspiro Medical Ltd., an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. Inspiro's Inspiromatic is a "smart" easy-to-use dry powder inhaler with several advantages over existing devices.

17 Apr 2014

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression.

16 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

16 Apr 2014

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.

15 Apr 2014

Researcher develops novel IBT to help opioid-dependent Vermonters

Opioid dependence - addiction to heroin and prescription painkillers - has reached epidemic levels across the country, with treatment waitlists also at an all-time high.

11 Apr 2014

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces today positive final results for the first clinical trial on its innovative formulation combining insulin analog glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

20 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Ludwig Cancer Research and Agenus Inc. today announced the selection of three monoclonal antibody checkpoint modulators (CPMs) that Agenus is advancing into preclinical development.

7 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

Georgia Regents Medical Center is among about a dozen centers nationally exploring the potential of a new drug that may offer relief to people with Parkinson's who have failed standard approaches to treating constipation.

5 Mar 2014

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2013.

4 Mar 2014

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Researchers found initial confirmation that a novel scaffold protein previously unassociated with the mu opioid receptor (MOR) regulates MOR-induced signaling activation.

4 Mar 2014

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus.

3 Mar 2014

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus.

28 Feb 2014

H4 receptor activation plays part in NSCLC progression

Histamine H4 receptor activation decreases epithelial-to-mesenchymal transmission in non-small-cell lung cancer, Chinese research shows.

27 Feb 2014

Researchers examine what dosages of asthma medications works best in African Americans

The University of Illinois at Chicago has received funding from the National Institutes of Health to determine what combination and dosages of asthma medications works best to manage asthma in African Americans, who suffer much higher rates of serious asthma attacks, hospitalizations and asthma-related deaths than do white patients.

20 Feb 2014

IBM content analysis software helps identify patients at risk for developing heart failure

IBM today announced that Virginia health system Carilion Clinic has identified 8,500 patients at risk for developing heart failure in a pilot project that could lead to early intervention and better care for these patients.

20 Feb 2014

Agonist News and Research

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

New insights into possible common links between neurodegenerative diseases

OPKO Health enters into definitive agreement to acquire Inspiro Medical

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

Obeticholic acid meets primary composite endpoint in Phase III study

Researcher develops novel IBT to help opioid-dependent Vermonters

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Ludwig, Agenus to advance three monoclonal antibody checkpoint modulators into preclinical development

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Georgia Regents Medical Center explores new treatment for Parkinson's disease-related constipation

GTx provides clinical updates, reports financial results for fourth quarter and full year 2013

Novel scaffold protein regulates mu opioid receptor induced signaling activation

Scientists map key elements of immune overreaction triggered by influenza virus infection

TSRI scientists describe severe immune overreaction caused by flu infections

H4 receptor activation plays part in NSCLC progression

Researchers examine what dosages of asthma medications works best in African Americans

IBM content analysis software helps identify patients at risk for developing heart failure

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News